Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17374802 | 0.98 | CES2 (0.55) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL11395919 | 0.98 | CES2 (0.55) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL27752426 | 0.98 | CES2 (0.55) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL904746 | 0.98 | CES2 (0.55) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL12134906 | 0.91 | CES2 (0.52) | DPP7CES2CHRM2CHRM4CHRM1 | |
| SCHEMBL32676289 | 0.91 | GNAI3 (0.64) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL6271110 | 0.91 | GNAI3 (0.64) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL5319167 | 0.89 | CES2 (0.55) | DPP7CES2CHRM2CHRM4CHRM1 | |
| SCHEMBL25469804 | 0.88 | GNAI3 (0.57) | DPP7CES2GNAI3GNAO1GNAI1 | |
| SCHEMBL7272048 | 0.88 | NOD1 (0.57) | DPP7GRIK1GRIK2SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | DPP7 3379/4885CES2 4290/4885GNAI3 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.